List of stock repurchases of Hong Kong stocks: 43 stocks were repurchased by the company. On December 12, a total of 43 Hong Kong stocks were repurchased by the company, and the repurchase amount of 8 stocks exceeded HK$ 10 million. Among them, Tencent Holdings, AIA and Samsonite have the largest repurchase amounts, with the company repurchasing HK$ 704 million, HK$ 61,711,300 and HK$ 34,247,500 respectively. As of December 12, 274 Hong Kong stocks have been repurchased by the company this year, and the cumulative repurchase amount of 62 stocks during the year exceeded HK$ 100 million. Among them, Tencent Holdings, HSBC Holdings and AIA have the largest cumulative repurchase amount during the year, with the company repurchasing HK$ 104.602 billion, HK$ 40.706 billion and HK$ 31.059 billion respectively.The MSCI Asia Pacific Index fell 1% to 185.63.Maotai Group had an exchange discussion with Huawei. Kweichow Moutai official news on December 13th. On December 12th, Zhang Pingan, managing director of Huawei Technologies Co., Ltd. and CEO of Huawei Cloud, visited Maotai and held an exchange discussion with Zhang Deqin, Party Secretary and Chairman of Maotai Group.
The CSI convertible bond index opened lower by 0.03%. Lide convertible bonds rose by more than 7%, and Weipai convertible bonds rose by more than 4%; Z-mode convertible bonds fell by nearly 3%, while Fuxin convertible bonds and Yinxin convertible bonds fell by nearly 2%.The Hang Seng Index of Hong Kong stocks opened lower by 0.78%, the index of state-owned enterprises fell by 0.88%, and the branch index opened lower by 1.01%.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.
In the exchange market, the national debt rose the most, with "National Debt 2404" rising more than 4%, "National Debt 23", "Special Country 24 03" and "Special Country 24 01" rising nearly 1%.The Nikkei 225 index fell to 1%.Yin Xiyue continued to exercise the presidential power to submit the consent of the appointment of the chief justice to the National Assembly. According to the information system of the Korean National Assembly's motion, South Korean President Yin Xiyue submitted the consent of the appointment of the chief justice to the National Assembly on the 12 th, and said that "with the end of the term of office of the chief justice, in order to appoint a successor judge, the consent of the National Assembly is requested." Yin Xiyue delivered a speech to the people on the 12th, refused to end his term of office ahead of schedule, and successively approved 42 bills and enforcement orders, and also submitted a consent case for the appointment of the chief justice to continue to exercise the presidential power. According to the Korean Constitution, the Chief Justice shall be submitted by the President of the Grand Court of Korea (the High Court) and appointed by the President with the consent of the National Assembly. (CCTV News)
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide
Strategy guide 12-14